Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Green Cross Holdings Corporation (005250.KS)
Yongin-Si, KR
Green Cross Holdings Corporation operates as a leading biotechnology enterprise with a diverse portfolio of pharmaceutical products. These include plasma derivatives, both prescription and over-the-counter medications, and specific treatments for Hunter syndrome. The company is also a key manufacturer of vaccines, covering diseases such as hemorrhagic fever, varicella, hepatitis-B, and influenza. Beyond its commercial offerings, Green Cross Holdings commits significant resources to the research and development of cutting-edge solutions in oncology, immunology, and cell therapy. It additionally supplies recombinant protein therapies for hemophilia. To foster the creation of new drugs and advanced technologies, the company engages in strategic partnerships and collaborations with other biotech firms and academic institutions. Established in 1967, Green Cross Holdings is headquartered in Yongin, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.74% | -3.98% | +7.38% | -5.28% | -3.56% | -3.14% | +13.46% | -3.92% | -59.07% | -55.72% | +280.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+11.2% ★ Q1'26: +8.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-389.3% Q1'26: -690.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1.8% Q1'26: -21.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+1.4% ★ Q1'26: +0.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.1% ★ Q1'26: +0.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×10.50× Q1'26: 13.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
2.45T
est: 113.80B (+2,054.2%)
|
113.80B
113.80B – 113.80B
+0.0% YoY
|
113.40B
113.40B – 113.40B
-0.4% YoY
|
115.80B
115.80B – 115.80B
+2.1% YoY
|
| EBITDA |
142.16B
est: 8.65B (+1,542.7%)
|
8.65B
8.65B – 8.65B
+0.0% YoY
|
8.62B
8.62B – 8.62B
-0.4% YoY
|
8.81B
8.81B – 8.81B
+2.1% YoY
|
| EBIT |
34.99B
est: 3.98B (+779.8%)
|
3.98B
3.98B – 3.98B
+0.0% YoY
|
3.96B
3.96B – 3.96B
-0.4% YoY
|
4.05B
4.05B – 4.05B
+2.1% YoY
|
| Net Income |
-69.51B
est: 31.17B (-323.0%)
|
31.17B
31.17B – 31.17B
+0.0% YoY
|
30.40B
30.40B – 30.40B
-2.5% YoY
|
31.31B
31.31B – 31.31B
+3.0% YoY
|
| SGA |
228.44B
est: 13.75B (+1,561.6%)
|
13.75B
13.75B – 13.75B
+0.0% YoY
|
13.70B
13.70B – 13.70B
-0.4% YoY
|
13.99B
13.99B – 13.99B
+2.1% YoY
|
| EPS |
-1,531.06
est: 687.00 (-322.9%)
|
687.00
687.00 – 687.00
+0.0% YoY
|
670.00
670.00 – 670.00
-2.5% YoY
|
690.00
690.00 – 690.00
+3.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex 200 Mid-Small 226980.KS | 0.26% | 35.1K | 0.30% |
| 2 | Kodex Healthcare 266420.KS | 0.20% | 93.0K | 0.09% |
| 3 | Kodex Dividend Value 325020.KS | 0.05% | 43.9K | 0.30% |
| 4 | Kodex 200 Intrinsic Value 223190.KS | 0.03% | 5.8K | 0.30% |
| 5 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.03% | 527.3K | 0.58% |
| 6 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.02% | 8.8K | 0.54% |
| 7 | Kodex KOSPI 226490.KS | 0.02% | 141.9K | 0.15% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 17.2K | 0.42% |
| 9 | Kodex 200TR 278530.KS | 0.01% | 770.8K | 0.05% |
| 10 | Samsung KODEX 200 ETF 069500.KS | 0.01% | 2.45M | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yong-Jun Huh | CEO & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 005250.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
